Bayer and Kumquat Biosciences have entered an exclusive $1.3 billion collaboration to develop and commercialize inhibitors targeting the KRAS G12D mutation, a driver in multiple hard-to-treat cancers including pancreatic, colorectal, and non-small cell lung cancers. This partnership follows the FDA clearance of Kumquat's IND application and aims to address a significant unmet need by targeting this historically “undruggable” oncogenic mutation with precision oncology therapeutics.